Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and
Brief Summary:
This clinical research study has 2 parts: lead-in and Part 2.
The goal of the safety lead-in portion of this study is to find the highest tolerable dose of the combination of clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL).
The goal of Part 2 of this clinical research study is to learn if this drug combination can help to control the disease. This will also be studied in the safety lead-in.
The safety of this drug combination will be studied in both parts of the study.